[{"id":"4829b067-17e9-4303-a9f1-a51640780137","acronym":"","url":"https://clinicaltrials.gov/study/NCT07211737","created_at":"2025-10-11T01:28:20.312Z","updated_at":"2025-10-11T01:28:20.312Z","phase":"Phase 1","brief_title":"NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","source_id_and_acronym":"NCT07211737","lead_sponsor":"Baylor College of Medicine","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2043","study_completion_date":" 12/01/2043","last_update_posted":"2025-10-08"},{"id":"5cc7e0ed-f106-4a96-bfa9-c63f255c96f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06850506","created_at":"2025-03-03T10:01:05.906Z","updated_at":"2025-03-03T10:01:05.906Z","phase":"","brief_title":"Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment","source_id_and_acronym":"NCT06850506","lead_sponsor":"Peking University People's Hospital","biomarkers":" CDH6","pipe":"","alterations":" ","tags":["CDH6"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-27"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"506639ea-1f9f-4169-b1e7-f028c834b64f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04870944","created_at":"2021-05-04T12:53:25.071Z","updated_at":"2025-02-25T15:12:04.041Z","phase":"Phase 1/2","brief_title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","source_id_and_acronym":"NCT04870944","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBL0137"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/28/2022","start_date":" 01/28/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"0811eebd-2541-4c17-9f6e-9259710f1407","acronym":"TARGET-RT","url":"https://clinicaltrials.gov/study/NCT06796543","created_at":"2025-02-25T16:28:16.453Z","updated_at":"2025-02-25T16:28:16.453Z","phase":"","brief_title":"Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","source_id_and_acronym":"NCT06796543 - TARGET-RT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EFS","pipe":"","alterations":" ","tags":["EFS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-29"},{"id":"c515fc0a-eb3f-4509-a7dc-e23a2f9595b0","acronym":"REGO-EWING","url":"https://clinicaltrials.gov/study/NCT05830084","created_at":"2023-04-26T14:04:47.284Z","updated_at":"2025-02-25T17:26:10.222Z","phase":"Phase 1","brief_title":"Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma","source_id_and_acronym":"NCT05830084 - REGO-EWING","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/16/2023","start_date":" 06/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-11-28"},{"id":"9f54073b-404a-456d-9f9e-2ad505dd2ab3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06500819","created_at":"2025-02-26T14:37:02.227Z","updated_at":"2025-02-26T14:37:02.227Z","phase":"Phase 1","brief_title":"Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT06500819","lead_sponsor":"Stanford University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-10-31"},{"id":"3188e8e3-1740-4804-8e06-d28ce9d7d16c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616560","created_at":"2021-01-19T20:33:38.892Z","updated_at":"2024-07-02T16:34:37.507Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","source_id_and_acronym":"NCT04616560","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Suspended","enrollment":" Enrollment 27","initiation":"Initiation: 03/08/2021","start_date":" 03/08/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-06"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"d2ef91c8-34da-461e-a797-3af5e0d2863c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942456","created_at":"2023-07-12T15:08:57.209Z","updated_at":"2024-07-02T16:35:04.015Z","phase":"","brief_title":"Soluble B7-H3 as a Biomarker for Osteosarcoma","source_id_and_acronym":"NCT05942456","lead_sponsor":"Peking University People's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-14"},{"id":"a339dfb3-6028-4f3a-ac08-8ffbfee76968","acronym":"","url":"https://clinicaltrials.gov/study/NCT05703854","created_at":"2023-01-30T18:59:49.752Z","updated_at":"2024-07-02T16:35:07.538Z","phase":"Phase 1/2","brief_title":"Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma","source_id_and_acronym":"NCT05703854","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-04-25"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"fbc9f7d7-d0d2-47e2-adf9-dee22a15f587","acronym":"","url":"https://clinicaltrials.gov/study/NCT03721068","created_at":"2021-01-18T18:14:20.673Z","updated_at":"2024-07-02T16:35:08.050Z","phase":"Phase 1","brief_title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","source_id_and_acronym":"NCT03721068","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IL15","pipe":"","alterations":" ","tags":["IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 06/19/2024","primary_completion_date":" 06/19/2024","study_txt":" Completion: 06/19/2039","study_completion_date":" 06/19/2039","last_update_posted":"2024-04-23"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"ab53141c-faa5-4818-bfa6-8bc2baf852f9","acronym":"DOSa","url":"https://clinicaltrials.gov/study/NCT04668300","created_at":"2024-04-15T18:24:09.850Z","updated_at":"2024-07-02T16:35:09.706Z","phase":"Phase 2","brief_title":"Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma","source_id_and_acronym":"NCT04668300 - DOSa","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD73 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD8 • PD-1 • CD73 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-15"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"}]